tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Exact Sciences price target lowered to $66 from $75 at TD Cowen

TD Cowen analyst Dan Brennan lowered the firm’s price target on Exact Sciences (EXAS) to $66 from $75 and keeps a Buy rating on the shares. The firm notes the stock traded off post close, this despite posting a strong Q2. The issue was the company’s CRC blood data was a big disappointment. But the good news is, TD Cowen points out, Exact Sciences moved aggressively, signing a deal with competitor Freenome to get access to their blood-based CRC test and pipeline, with FDA approval expected in 2026. The firm says the selloff looks overdone.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1